Drug Target (or Biomarker) DOCK3: Unlocking the Potential of Drug Development

Target Name: DOCK3

NCBI ID: G1795

DOCK3

Drug Target (or Biomarker) DOCK3: Unlocking the Potential of Drug Development

The discovery of drug targets and biomarkers is a critical aspect of drug development. Drug targets are molecules that are associated with the disease or disorder a drug aims to treat, while biomarkers are indicators of the disease or disorder that a drug targets. Identifying a drug target and developing a reliable biomarker can significantly improve drug development efficiency and reduce the risk of developing side effects. One such drug target and biomarker that has gained significant attention in recent years is DOCK3.

DOCK3: The Enigma of Docking

DOCK3, short for Deconstructive Analysis of Chemical Compounds to Identify Three-dimensional Compounds, is a protein-coding gene that was first identified in 2006. It is a key regulator of cell adhesion and has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. DOCK3 plays a crucial role in the regulation of cell-cell adhesion by controlling the distribution and activity of adhesion molecules such as cadherins and immunoglobulin-like cell adhesion molecules (Ig-CAMs).

DOCK3 is a transmembrane protein that is expressed in various tissues and cells, including epithelial cells, endothelial cells, and neural cells. Its function is to regulate the distribution and activity of adhesion molecules, which are essential for cell-cell adhesion and tissue repair. DOCK3 has been shown to play a crucial role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

DOCK3 as a Drug Target

DOCK3 has been identified as a potential drug target due to its involvement in various diseases. One of the primary reasons for identifying DOCK3 as a drug target is its role in the regulation of cell-cell adhesion. DOCK3 has been shown to control the distribution and activity of adhesion molecules, which are essential for cell-cell adhesion. This suggests that DOCK3 may be a useful target for drugs that target cell-cell adhesion.

DOCK3 has also been shown to play a role in the regulation of various signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, differentiation, and repair, and is a key regulator of cancer growth. DOCK3 has been shown to be involved in the regulation of TGF-β signaling by controlling the distribution and activity of adhesion molecules.

DOCK3 as a Biomarker

DOCK3 has also been identified as a potential biomarker for various diseases. One of the primary reasons for identifying DOCK3 as a biomarker is its role in the regulation of cell-cell adhesion. DOCK3 has been shown to control the distribution and activity of adhesion molecules, which are essential for cell-cell adhesion. This suggests that DOCK3 may be a useful target for drugs that target cell-cell adhesion.

DOCK3 has also been shown to play a role in the regulation of various signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, differentiation, and repair, and is a key regulator of cancer growth. DOCK3 has been shown to be involved in the regulation of TGF-β signaling by controlling the distribution and activity of adhesion molecules.

Conclusion

In conclusion, DOCK3 is a protein-coding gene that has gained significant attention due to its involvement in various diseases. Its role in the regulation of cell-cell adhesion and TGF-β signaling makes it a potential drug target and biomarker. Further research is needed to fully understand the functions of DOCK3 and its potential as a drug target and biomarker.

Protein Name: Dedicator Of Cytokinesis 3

Functions: Potential guanine nucleotide exchange factor (GEF). GEF proteins activate some small GTPases by exchanging bound GDP for free GTP. Its interaction with presenilin proteins as well as its ability to stimulate Tau/MAPT phosphorylation suggest that it may be involved in Alzheimer disease. Ectopic expression in nerve cells decreases the secretion of amyloid-beta APBA1 protein and lowers the rate of cell-substratum adhesion, suggesting that it may affect the function of some small GTPase involved in the regulation of actin cytoskeleton or cell adhesion receptors (By similarity)

The "DOCK3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DOCK3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets